



Resonance Health Limited

ASX: RHT

Annual General Meeting

24th November 2016



Disclaimer

This presentation contains forward looking statements which may be subject to significant uncertainties outside of the Company's control.

No representation is made as to the accuracy or reliability of forward looking statements or the assumptions on which they are based.

Actual future events may vary from these forward looking statements and you are cautioned not to place undue reliance on any forward looking statement.












Resonance Health Limited

- RHT develops and delivers non-invasive quantitative medical imaging software and services
- Market capitalisation ~ AU\$10M
(approx. 400 million shares on issue)
- Significant investment in marketing, R&D and team
- Net loss reported of \$384k for FY 2015/16
- Cash on hand at 30 September of \$2.0M




Year in Review: Growth and Development

FerriScan		
Grow established markets	<ul style="list-style-type: none"> Record clinical image analyses 25 new sites 	
Develop new markets	<ul style="list-style-type: none"> Sickle Cell: 25% sales increase USA Cancer survivors 	
HepaFat-Scan		
Generate data & publications	<ul style="list-style-type: none"> 8 studies with KOLs & paper published 	
Diversify (liver and other organs systems)		
Fibrosis test prototype	<ul style="list-style-type: none"> Investigate commercial readiness 	
Bone marrow iron	<ul style="list-style-type: none"> Progress to commercial product 2017 	
Pancreatic fat	<ul style="list-style-type: none"> New investigational product (diabetes) 	
Spleen volume	<ul style="list-style-type: none"> New investigational product (clinical trial) 	
Value-add (combination products)		
FerriScan + HepaFat-Scan	<ul style="list-style-type: none"> Hyperferritinaemia & Cancer survivors 	
HepaFat-Scan + Pancreatic fat	<ul style="list-style-type: none"> Metabolic syndrome / Diabetes T2 	



Year in Review: HepaFat-Scan Studies



Strategy

1

FerriScan & HepaFat-Scan

- Grow established and new markets
- Sickle cell
- Cancer survivors
- Collaborative programs
- Combined use of FS & HFS

2

Reimbursement

- Evaluate potential new CPT code submission
- German reimbursement
- Italian reimbursement

3

New Advances

- Efficiencies and further automation of established products
- New applications
- New collaborations

4

Diversify

- Broaden product portfolio
- Bone marrow iron
- Pancreatic fat
- Spleen volume
- Inflammation / fibrosis



The Liver and Beyond

- Expertise in the liver → other organ systems
 - Heart, Bone Marrow, Spleen and **Pancreas**
- HepaFat-Scan + Pancreatic fat
 - Fatty Liver, Diabetes, Metabolic Syndrome

NAFLD / NASH

Obesity epidemic (developed countries):

- 20 – 30% have NAFLD
- 2 - 3% at risk of inflammation (NASH) & fibrosis

At risk of NASH

USA: ~10 M

China & India: ~50 M

Diabetes Type II

Worldwide: ~380 M



FerriScan: Strategy

Develop new markets

- 1) Sickle Cell Disease (USA – 100k patients)
 - 15% patients receive regular blood transfusions
 - Evidence shows benefit of FerriScan
 - Guidelines in place

- 2) Cancer Survivors (USA – 350k paediatrics)
 - 5 – 10% receive > 10 blood transfusions
 - Marketing campaign launched
 - Long term follow-up centres
 - Iron overload audit with key sites

“Cancer survivors with excess iron may be exposed to this iron for years ahead if untreated, so timely monitoring and reduction of iron burden is an important goal¹”



HepaFat-Scan: Strategy


- KOLs using in 8 active studies
 - Generate evidence to enhance uptake
 - 2 studies near completion
- Pharma trials

Combination with FerriScan


- Cancer Survivors
 - Transfusions → Iron overload
 - Chemotherapy → Fatty liver
- Unexplained Hyperferritinaemia
 - Raised serum ferritin level
 - Is it caused by iron overload or fatty liver?

Combination with Pancreatic Fat

- Metabolic Syndrome / Diabetes



HEALTHY LIVER



FATTY LIVER




Reimbursement: Strategy

- FerriScan currently reimbursed in:
 - UK (NHS trusts)
 - Canada (MOH Ontario)
 - US (selected payers)
 - Germany (case-by-case)
- 1) USA
 - Obtain advice around renewed CPT application
- 2) Germany
 - Finalising reimbursement application
- 3) Italy
 - Lobbying government through KOL advocacy



New Advances: Strategy

- Advances in Computer Science (Machine Learning)
 - Develop new low cost LIC measurement product
 - Opens large volume markets, e.g. developing countries
 - Application in established RH technology (efficiencies)
- Potential for new products/partnerships
- Collaborations
 - Other imaging diagnostic companies
 - Radiology partners
 - Research partners
 - Pharma companies



Diversify: Strategy

New investigational products

- Bone marrow iron assessment
 - 50k+ transplants pa → regulatory filing
- Pancreatic fat assessment (Diabetes)
- Organ volume measurements
- Standardised assessment of biopsy

R&D

- Non-invasive measurement of
 - Liver inflammation
 - Liver fibrosis
- Proof-of-concept
- Application: NAFLD, NASH



Product Status Summary

Research

Proof of Concept

Validation

Regulatory Clearance

On Market

Reimbursement

FerriScan

UK / Can

Cardiac T2*

Can

HepaFat-Scan

Bone Marrow Iron

Pancreatic Fat

Fibrosis

Machine Learning

Inflammation



Summary: 2017 Focus

- Investing in growth and diversification
- New markets for established products
 - Sickle cell disease
 - Cancer survivors
 - Unexplained hyperferritinaemia
- FerriScan & HepaFat-Scan combination
- Revisiting reimbursement
 - CPT code USA
 - New: Germany and Italy
- Expansion of product pipeline
 - Bone marrow iron regulatory submission
 - Pancreatic fat (metabolic syndrome/diabetes)
 - Potential low cost LIC measurement



Resonance



Health

Be Better Informed

www.resonancehealth.com

